Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus STERI STAT.
DEXAMETHASONE INTENSOL vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of gene transcription.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
0.75-9 mg/day orally in divided doses every 6-12 hours; for anti-inflammatory/immunosuppressive effects, initial dose 0.75-9 mg/day; for cerebral edema, 10 mg IV then 4 mg IM/IV every 6 hours.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours (adults); clinically, biological half-life (duration of HPA axis suppression) is longer (24-72 hours).
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal (approximately 65-80% as metabolites, <10% as unchanged drug); biliary/fecal (minor).
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid